exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087792 RNA Name: hsa-miR-149-5p RNA Type: miRNA Chromosome: chr2 Starnd: + Coordinate: Start Site(bp): 240456015 End Site(bp): 240456037 External Links: hsa-miR-149-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AMOTL2 chr3 134355874 134375479 - CDT1 chr16 88803789 88809258 + FOXP1 chr3 70952817 71583993 - FZD5 chr2 207762598 207769906 - GALNT2 chr1 230057990 230282122 + GNPTAB chr12 101745499 101830959 - ITGA11 chr15 68296532 68432163 - ITGA5 chr12 54395261 54419266 - MAP3K3 chr17 63622415 63696303 + MLLT1 chr19 6210381 6279975 - PHLPP2 chr16 71637835 71724701 - RAB31 chr18 9708275 9862551 + RCC2 chr1 17406760 17439677 - SLC6A6 chr3 14402576 14489349 + SMG5 chr1 156249224 156282825 - WDR36 chr5 111091716 111130502 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001731 chr7 100731990 100738448 + hsa_circ_0000241 chr10 70847874 70856944 + hsa_circ_0000907 chr19 17212469 17213367 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AL035458.2 chr20 34234840 34281173 - AL160006.1 chr1 110058340 110062555 + MALAT1 chr11 65497688 65506516 + MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + SNHG8 chr4 118278709 118285316 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.